[go: up one dir, main page]

DE60114194D1 - Vip-verwandte peptide zur behandlung von sexuellen funktionsstörungen bei frauen - Google Patents

Vip-verwandte peptide zur behandlung von sexuellen funktionsstörungen bei frauen

Info

Publication number
DE60114194D1
DE60114194D1 DE60114194T DE60114194T DE60114194D1 DE 60114194 D1 DE60114194 D1 DE 60114194D1 DE 60114194 T DE60114194 T DE 60114194T DE 60114194 T DE60114194 T DE 60114194T DE 60114194 D1 DE60114194 D1 DE 60114194D1
Authority
DE
Germany
Prior art keywords
treatment
vip
conjugate
women
vaginal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60114194T
Other languages
English (en)
Other versions
DE60114194T2 (de
Inventor
Illana Gozes
Matityahu Fridkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Yeda Research and Development Co Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL13627400A external-priority patent/IL136274A0/xx
Priority claimed from IL13897100A external-priority patent/IL138971A0/xx
Application filed by Ramot at Tel Aviv University Ltd, Yeda Research and Development Co Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of DE60114194D1 publication Critical patent/DE60114194D1/de
Application granted granted Critical
Publication of DE60114194T2 publication Critical patent/DE60114194T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2278Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DE60114194T 2000-05-22 2001-05-22 Vip-verwandte peptide zur behandlung von sexuellen funktionsstörungen bei frauen Expired - Fee Related DE60114194T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IL13627400A IL136274A0 (en) 2000-05-22 2000-05-22 Pharmaceutical compositions comprising vip-related peptides
IL13627400 2000-05-22
IL13897100 2000-10-12
IL13897100A IL138971A0 (en) 2000-10-12 2000-10-12 Pharmaceutical compositions comprising vip-related peptides
PCT/IL2001/000460 WO2001090144A2 (en) 2000-05-22 2001-05-22 Vip-related peptides for the treatment of sexual disorders in women

Publications (2)

Publication Number Publication Date
DE60114194D1 true DE60114194D1 (de) 2006-03-02
DE60114194T2 DE60114194T2 (de) 2006-07-13

Family

ID=26323949

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60114194T Expired - Fee Related DE60114194T2 (de) 2000-05-22 2001-05-22 Vip-verwandte peptide zur behandlung von sexuellen funktionsstörungen bei frauen

Country Status (8)

Country Link
US (1) US20050075284A1 (de)
EP (1) EP1292618B1 (de)
JP (1) JP2004517036A (de)
AT (1) ATE307144T1 (de)
AU (1) AU2001260580A1 (de)
CA (1) CA2409592A1 (de)
DE (1) DE60114194T2 (de)
WO (1) WO2001090144A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099003A1 (en) 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
US7198834B2 (en) * 2005-03-22 2007-04-03 Hewlett-Packard Development Company, L.P. Imaging media including interference layer for generating human-readable marking on optical media
AU2009228250B2 (en) * 2008-03-26 2015-03-19 Glanbia Nutritionals (Ireland) Ltd. Leucine-rich peptide compositions and methods for isolation
DK2533791T3 (en) * 2009-12-21 2017-05-08 Glanbia Nutritionals (Ireland) Ltd LEUCIN-PEPTID COMPOSITION AND PROCEDURE FOR FORMULATION
ES2395801B1 (es) * 2011-06-23 2014-06-06 María Carmen PARDINA PALLEJÀ "pentoxifilina por vía transvaginal para el tratamiento de la infertilidad"

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE101619T1 (de) * 1990-06-26 1994-03-15 Sanwa Kagaku Kenkyusho Co Vip-analogen und ihre verwendung.
US5998368A (en) * 1991-10-31 1999-12-07 Yeda Research And Development Co. Ltd. Derivatives of structurally modified VIP and pharmaceutical compositions containing them
BR9203277A (pt) * 1992-08-21 1994-03-01 Cesar Roberto Dias Nahoum Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
IL118003A0 (en) * 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
US6217886B1 (en) * 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
US20020004529A1 (en) * 1997-10-20 2002-01-10 Gary W. Neal Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US6031002A (en) * 1998-05-01 2000-02-29 Michael Ebert Method for enhancing female sexual response and a composition therefor
US6214849B1 (en) * 1999-04-29 2001-04-10 Lupin Laboratories Limited Use of nicorandil in treatment of sexual dysfunction or for enhancement of sexual function in mammals including humans

Also Published As

Publication number Publication date
ATE307144T1 (de) 2005-11-15
WO2001090144A2 (en) 2001-11-29
CA2409592A1 (en) 2001-11-29
US20050075284A1 (en) 2005-04-07
AU2001260580A1 (en) 2001-12-03
DE60114194T2 (de) 2006-07-13
EP1292618A2 (de) 2003-03-19
EP1292618B1 (de) 2005-10-19
JP2004517036A (ja) 2004-06-10
WO2001090144A3 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
EA200201000A1 (ru) Гормон-заместительная терапия
WO2003000343A3 (en) Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
DE69917066D1 (de) Zusammensetzungen und methoden zur verbesserung von sexuellen funktionsstörungen bei frauen
ES2170050T3 (es) Metodos y composiciones para inducir la ereccion.
ATE365045T1 (de) Vermehrung des weich- sowie des knochengewebes anhand von aus muskeln stammenden vorläuferzellen,sowie damit verbundene zusammensetzungen und behandlungsformen
ATE184794T1 (de) Zusammensetzungen, die troxerutin als komplex mit phosphatidylcholin enthalten, zur topischen behandlung von erektionsimpotenz
ATE245992T1 (de) Progestagen-freie formulierungen von gnrh und estrogen zur behandlung von benignen gynäkologischen störungen
EA200301022A1 (ru) Гормональная заместительная терапия
MXPA02011288A (es) Tioacetamidas substituidas.
WO2006023496A3 (en) Vaginal cream compositions, kits thereof and methods of using thereof
MXPA04005783A (es) Formulacion farmaceutica que comprende ciclosporina y uso de la misma.
CY1107478T1 (el) Η χρηση της τραμαδολης για καθυστερηση της εκσπepματισης
DE60114194D1 (de) Vip-verwandte peptide zur behandlung von sexuellen funktionsstörungen bei frauen
PT1109814E (pt) 5-heterociclil pirazol¬4,3-d|pirimidina-7-onas para o tratamento da disfuncao erectil masculina
BR0111002A (pt) Combinação de secretagogos do hormÈnio do crescimento e antidepressivos
DK1343472T3 (da) Thixotropisk næsespray
ES2134301T3 (es) Composicion farmaceutica para la profilaxis y el tratamiento de la eyaculacion precoz.
US20050214244A1 (en) Menopause homeopathic formulations
Bartlik et al. Medications with the potential to enhance sexual responsivity in women
WO2003034998A3 (en) Composition and method for treating erectile dysfunction and reducing fibrosis in erectile tissue of the human penis
EP0971722B1 (de) Aphrodisiakum zur anwendung an den geschlechtsorganen
BRPI0416202A (pt) formulações inibidoras de fosfodiesterase v
WO2004011029A3 (en) Pharmaceutical compositions for penis enlargement
NO20024331L (no) Behandling av lidelser relatert til det serotonerge system
BR0108732A (pt) Composição farmacêutica para a prevenção e tratamento da progressão da fibrose e cirrose hepática, seu uso e método para a prevenção e tratamento da fibrose e cirrose hepática

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee